Nautilus Biotechnology has announced that it has raised $76 million in a Series B offering that closed this week, bringing Nautilus’ total funding to in excess of $100 million. The funding round was led by firms associated with Microsoft co-founder Paul G. Allen and Amazon founder Jeff Bezos. The Nautilus platform seeks to deliver single-molecule sensitivity more quickly and less expensively than is possible with existing technologies. This deeper, richer understanding of proteins is expected to enable a dramatic acceleration of scientific research, significantly improve the success rate of drug development, and speed the adoption of personalized and predictive medicine. Learn More